Reteplase

BLOOD AND BLOOD FORMING ORGANS

Key facts

Reteplase is a drug catalogued in DrugCentral. It was first approved by the FDA in 1996. DrugCentral lists 1 molecular target, including PLG. Recorded indications include Acute myocardial infarction.

• Molecular targets: PLG (1 listed in DrugCentral).
• Indications: Acute myocardial infarction.
• ATC code: B01AD07 (Enzymes).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Acute myocardial infarction

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
Plasminogen	PLG	activator	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1996-10-30	FDA	—	EKR THERAP

ATC classification

ATC code	Therapeutic hierarchy
B01AD07	BLOOD AND BLOOD FORMING ORGANS › ANTITHROMBOTIC AGENTS › ANTITHROMBOTIC AGENTS › Enzymes

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 133652-38-7
• InChIKey: —
• PubChem CID: 5526

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Reteplase used for?

DrugCentral lists the following indications for Reteplase: Acute myocardial infarction.

How does Reteplase work?

Its molecular targets in DrugCentral include PLG (activator).

When was Reteplase first approved?

Reteplase was first approved by the FDA in 1996.

Sources

• DrugCentral drug card 5044 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2107885 — compound record and bioactivity
• PubChem CID 5526 — chemical identifiers
• DrugBank DB00015 — drug record
• FDA UNII DQA630RIE9 — substance identity
• DailyMed: FDA labels for Reteplase — current prescribing information (label search)
• UniProt P00747 (PLG) — target protein

How this page is built: methodology · editorial policy & corrections.